Key facts
- This page summarizes Brenda Mann's Form 4 filing for EYEGATE PHARMACEUTICALS INC (KPRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 03 Nov 2021, 16:16.
Brenda Mann - 02 Nov 2021 Form 4 Insider Report for EYEGATE PHARMACEUTICALS INC (KPRX)
- Reporting relationship
- VP of Research & Development
- Issuer ticker
- KPRX
- Reported as of
- 02 Nov 2021
- Net transaction value
- -$123
- SEC form
- 4
- Accepted by SEC
- 03 Nov 2021, 16:16:00 UTC
- Prior SEC filing
- 05 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sarah Romano, Attorney-in-Fact*
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Brenda Mann filed Form 4 for EYEGATE PHARMACEUTICALS INC (KPRX) on 03 Nov 2021.
Change
- Previous filing in this sequence was filed on 05 Oct 2021.
- Current net transaction value: -$123.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KPRX
transaction
Common Stock
Tax liability
- Transaction value
- $123
- Shares
- -62
- Change %
- -0.41%
- Price
- $1.98
- Shares after
- 15,136
- Date
- 02 Nov 2021
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Brenda Mann is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
Sale of shares to cover taxes due on restricted stock that vested on 11/01/2021.